[go: up one dir, main page]

WO2000015784A3 - Recepteur edg6 (gene de differentiation de cellules endotheliales) humain et murin couple a des proteines g et son utilisation - Google Patents

Recepteur edg6 (gene de differentiation de cellules endotheliales) humain et murin couple a des proteines g et son utilisation Download PDF

Info

Publication number
WO2000015784A3
WO2000015784A3 PCT/DE1999/002871 DE9902871W WO0015784A3 WO 2000015784 A3 WO2000015784 A3 WO 2000015784A3 DE 9902871 W DE9902871 W DE 9902871W WO 0015784 A3 WO0015784 A3 WO 0015784A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
protein
edg6
coupled
terminal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE1999/002871
Other languages
German (de)
English (en)
Other versions
WO2000015784A2 (fr
Inventor
Markus Graeler
Guenter Bernhardt
Martin Lipp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Original Assignee
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19846979A external-priority patent/DE19846979A1/de
Application filed by Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft filed Critical Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Priority to JP2000570311A priority Critical patent/JP2002525050A/ja
Priority to EP99948712A priority patent/EP1112365A2/fr
Priority to HK02100072.9A priority patent/HK1039791A1/zh
Publication of WO2000015784A2 publication Critical patent/WO2000015784A2/fr
Publication of WO2000015784A3 publication Critical patent/WO2000015784A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne le récepteur EDG6 couplé à des protéines G, et ses fragments, variantes et mutations. ainsi que son utilisation. Les domaines d'application de l'invention sont la biologie moléculaire, la pharmacie et la médecine. L'invention vise à isoler et à identifier un membre supplémentaire de la famille des récepteurs EDG, et à permettre l'utilisation de ce nouveau membre à des fins médicales. Ce nouveau récepteur EDG6 humain comprend 384 acides aminés de la séquence 1 comportant sept domaines transmembranaires. Ce récepteur présente un site de glycosylation potentielle N-terminal, trois sites de palmitoylation potentielle, 12 à 15 acides aminés placés à l'extrémité C-terminale du septième domaine transmembranaire, et quatre sites C-terminaux de phosphorylation potentielle catalysée par la protéine kinase C. L'invention concerne également l'utilisation du récepteur EDG6, de ses fragments, variantes et mutations et éventuellement de ses partenaires de liaison pour des méthodes et traitements thérapeutiques.
PCT/DE1999/002871 1998-09-11 1999-09-10 Recepteur edg6 (gene de differentiation de cellules endotheliales) humain et murin couple a des proteines g et son utilisation Ceased WO2000015784A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2000570311A JP2002525050A (ja) 1998-09-11 1999-09-10 ヒト及びマウスｇタンパク質結合受容体ｅｄｇ６（内皮分化遺伝子）及びその用途
EP99948712A EP1112365A2 (fr) 1998-09-11 1999-09-10 Recepteur edg6 (gene de differentiation de cellules endotheliales) humain et murin couple a des proteines g et son utilisation
HK02100072.9A HK1039791A1 (zh) 1998-09-11 1999-09-10 人類及鼠科動物的g-蛋白質耦合edg6的接收體(內皮鑒別基因)及其使用的方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19843240.2 1998-09-11
DE19843240 1998-09-11
DE19846979A DE19846979A1 (de) 1998-09-11 1998-10-13 G-Protein gekoppelter Rezeptor EDG6 und seine Verwendung
DE19846979.9 1998-10-13

Publications (2)

Publication Number Publication Date
WO2000015784A2 WO2000015784A2 (fr) 2000-03-23
WO2000015784A3 true WO2000015784A3 (fr) 2000-08-17

Family

ID=26048985

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1999/002871 Ceased WO2000015784A2 (fr) 1998-09-11 1999-09-10 Recepteur edg6 (gene de differentiation de cellules endotheliales) humain et murin couple a des proteines g et son utilisation

Country Status (3)

Country Link
EP (1) EP1112365A2 (fr)
JP (1) JP2002525050A (fr)
WO (1) WO2000015784A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812335B1 (en) 1999-03-23 2004-11-02 The Regents Of The University Of California Human polypeptide receptors for lysophospholipids and sphingolipids and nucleic acids encoding the same
WO2004058149A2 (fr) 2002-12-20 2004-07-15 Merck & Co., Inc. 1-(amino)indanes et (1,2-dihydro-3-amino)-benzofuranes, benzothiophenes et indoles utilises en tant qu'agonistes du recepteur edg
US20050079549A1 (en) * 2003-07-23 2005-04-14 John Castracane Methods for modeling GPCRs and for producing ligand blocking and receptor activating antibodies for same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046620A1 (fr) * 1997-04-17 1998-10-22 Millennium Pharmaceuticals, Inc. Nouveau recepteur couple a la proteine g humaine
WO1998048016A1 (fr) * 1997-04-24 1998-10-29 Incyte Pharmaceuticals, Inc. Recepteur de type edg-1
WO1998050549A2 (fr) * 1997-05-07 1998-11-12 Human Genome Sciences, Inc. Deux recepteurs couples par des proteines g: gpcr2 induit par veb (ebi-2) et gpcr de type gde-1
WO1999035106A2 (fr) * 1997-12-30 1999-07-15 Nps Allelix Corp. Homologues de recepteurs edg-7 mammaliens

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046620A1 (fr) * 1997-04-17 1998-10-22 Millennium Pharmaceuticals, Inc. Nouveau recepteur couple a la proteine g humaine
WO1998048016A1 (fr) * 1997-04-24 1998-10-29 Incyte Pharmaceuticals, Inc. Recepteur de type edg-1
WO1998050549A2 (fr) * 1997-05-07 1998-11-12 Human Genome Sciences, Inc. Deux recepteurs couples par des proteines g: gpcr2 induit par veb (ebi-2) et gpcr de type gde-1
WO1999035106A2 (fr) * 1997-12-30 1999-07-15 Nps Allelix Corp. Homologues de recepteurs edg-7 mammaliens

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1996, ROCA ALFRED L ET AL: "Structure, characterization, and expression of the gene encoding the mouse Me1-1a melatonin receptor.", XP002137157, Database accession no. PREV199699134631 *
ENDOCRINOLOGY 1996, vol. 137, no. 8, 1996, pages 3469 - 3477, ISSN: 0013-7227 *
GRAELER MARKUS H ET AL: "EDG6, a novel G-protein-coupled receptor related to receptors for bioactive lysophospholipids, is specifically expressed in lymphoid tissue.", GENOMICS OCT. 15, 1998, vol. 53, no. 2, 15 October 1998 (1998-10-15), pages 164 - 169, XP002137156, ISSN: 0888-7543 *

Also Published As

Publication number Publication date
JP2002525050A (ja) 2002-08-13
EP1112365A2 (fr) 2001-07-04
WO2000015784A2 (fr) 2000-03-23

Similar Documents

Publication Publication Date Title
Oldberg et al. The primary structure of a cell-binding bone sialoprotein.
Bhatnagar et al. The role in cell binding of a β1-bend within the triple helical region in collagen αl (I) chain: structural and biological evidence for conformational tautomerism on fiber surface
Waggett et al. Characterization of collagens and proteoglycans at the insertion of the human Achilles tendon
Calzada et al. Identification of novel β1 integrin binding sites in the type 1 and type 2 repeats of thrombospondin-1
EP0861261A4 (fr) Sequences nucleotidiques et proteiques de genes delta de vertebres et procedes fondes sur ces dernieres
PT813545E (pt) Sequências nucleotídicas e proteicas de genes serrate de vertebrado e métodos nelas baseados
Heiska et al. Binding of the cytoplasmic domain of intercellular adhesion molecule-2 (ICAM-2) to α-actinin
NZ508381A (en) Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5)
US20080081785A1 (en) Paralytic Peptide For Use In Neuromuscular Therapy
DE69433747D1 (de) Calcitoninrezeptor
AU5369996A (en) Monoclonal antibody against human receptor protein 4-1bb and methods of its use for treatment of diseases
KR20030063344A (ko) 성장인자 복합체
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
Vanlingen et al. Ca2+ and calmodulin differentially modulate myo-inositol 1, 4, 5-trisphosphate (IP3)-binding to the recombinant ligand-binding domains of the various IP3 receptor isoforms
EP1702929A3 (fr) Utilisation thérapeutique de la protéine SMR 1 et dérivés actifs de celle-ci
RU2279890C2 (ru) Конъюгат, связывающий фибрин/фибриноген
WO2002086076A3 (fr) Polynucleotides et polypeptides associes au chemin nf-kb
US9725484B2 (en) Methods and compositions for the treatment of bone remodeling disorders
WO2000015784A3 (fr) Recepteur edg6 (gene de differentiation de cellules endotheliales) humain et murin couple a des proteines g et son utilisation
AU2256097A (en) A g protein-coupled receptor with an enlarged extracellular domain
HK1044023A1 (zh) Ox2受体同系物
ES2300625T3 (es) Peptido paralizante de musaraña para uso en terapia neuromuscular.
WO1999042127A3 (fr) Peptides derives de recepteurs agissant en tant que modulateurs de l'activite de ces recepteurs
Milani A new and refined injectable treatment for musculoskeletal disorders
Heal et al. A search within the IL-1 type I receptor reveals a peptide with hydropathic complementarity to the IL-1β trigger loop which binds to IL-1 and inhibits in vitro responses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 570311

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999948712

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09786926

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999948712

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999948712

Country of ref document: EP